ADAG

Adagene Inc. American Depositary Shares

$3.78 -4.79%

Recent alerts on ADAG

All signals →

SEC filing ADAG Reports $0 Revenue, $0 EPS, Announces $0 Buyback, Presents AACR 2026 Data on Muzastotug Triple Combination Therapy for HCC and MSS CRC

News India's Richest Man Sees Company Shares Dip After OFAC Request On Iranian LPG Allegations

News Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Get push alerts for ADAG

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS